Emerging Therapeutic Targets of Neuroendocrine Prostate Cancer

Area of Science:

• Oncology
• Cancer Biology
• Medical Research

Background:

• Treatment-emergent neuroendocrine prostate cancer (NEPC) is an aggressive and lethal malignancy.
• The increasing use of androgen receptor signaling inhibitors (ARSIs) in earlier prostate cancer stages correlates with a rise in NEPC prevalence.
• There is an urgent need for effective therapies to combat this challenging disease.

Purpose of the Study:

• To review and summarize recent advancements in identifying and targeting NEPC.
• To highlight emerging therapeutic strategies for NEPC.

Main Methods:

• Literature review of recent preclinical and clinical studies.
• Analysis of emerging therapeutic targets in NEPC.
• Evaluation of various treatment modalities targeting these identified pathways.

Main Results:

• Multiple novel therapeutic targets have been identified in NEPC.
• These targets are implicated in treatment-emergent lineage plasticity or are cell surface markers.
• Promising preclinical and clinical results have been observed with various therapeutic modalities.
• Treatment-emergent NEPC is a distinct and clinically significant subset of castration-resistant prostate cancer (CRPC).

Conclusions:

• Emerging therapeutic approaches for NEPC show encouraging efficacy and safety profiles.
• These novel therapies hold the potential to significantly improve outcomes for patients with NEPC.
• Continued research into NEPC targets and treatments is crucial.